![]() |
|
|
M Mortensen, PD Suzdak and C Thomsen
Department of Receptor Neurochemistry, Novo Nordisk A/S, Malov, Denmark.
Mice were exposed to lorazepam (4 mg/kg) or vehicle by continuous infusion by implanted (s.c.) osmotic minipumps that were removed after 7 days. Dose-response curves for stimulation of phosphoinositide (PI) hydrolysis by the selective metabotropic glutamate receptor (mGluR) agonist, (1S,3R)-1-aminocyclopentane dicarboxylic acid [(1S,3R)-ACPD] were performed with cortical slices from mice treated with lorazepam or vehicle for 7 days and subject to 0, 1, 2, 3, 4 and 7 days of withdrawal. The efficacy of (1S,3R)-ACPD to stimulate PI hydrolysis was increased significantly at 2 and 3 days of lorazepam withdrawal when compared with responses in control slices. The effect was blocked by the mGluR antagonist, L-2-amino-3-phosphonopropionate (L-AP3). Enhancement of PI hydrolysis in cortical slices from mice at 2 days of discontinuation from 7 days exposure to lorazepam was also observed with agonists of alpha 1 adrenergic and histamine receptors, but not with agonists of muscarinic or serotonin receptors when compared with responses in control slices. Intracerebroventricular infusion of L-AP3 significantly increased pentylenetetrazol-seizure threshold in mice withdrawn for 2 days from 7 days of exposure to lorazepam, but showed no effect in comparable vehicle-exposed mice. These data suggest that PI-coupled mGluRs may be implicated in regulation of GABAergic functionality as observed after withdrawal from prolonged exposure to lorazepam.
This article has been cited by other articles:
![]() |
P. Wahl, C. Foged, S. Tullin, and C. Thomsen Iodo-Resiniferatoxin, a New Potent Vanilloid Receptor Antagonist Mol. Pharmacol., January 1, 2001; 59(1): 9 - 15. [Abstract] [Full Text] |
||||
![]() |
D. Plenz and S. T. Kitai Regulation of the Nigrostriatal Pathway by Metabotropic Glutamate Receptors during Development J. Neurosci., June 1, 1998; 18(11): 4133 - 4144. [Abstract] [Full Text] [PDF] |
||||